Trials / Completed
CompletedNCT00268671
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study Objectives: * To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) * To determine the response rate of the recommended dose * To determine the safety and tolerability of the recommended dose
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2005-12-22
- Last updated
- 2009-12-07
Source: ClinicalTrials.gov record NCT00268671. Inclusion in this directory is not an endorsement.